KURA Kura Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KURA

Price (delayed)

$9.67

Market cap

$718.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$706.9M

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable ...

Highlights
The equity has contracted by 6% from the previous quarter but it has grown by 2.5% YoY
The debt is up by 34% since the previous quarter
The quick ratio has contracted by 18% from the previous quarter and by 5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kuraoncology.com
Peers: OMGA

Key stats

What are the main financial stats of KURA
Market
Shares outstanding
74.27M
Market cap
$718.21M
Enterprise value
$706.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$141.58M
EBITDA
-$140.73M
Free cash flow
-$117.21M
Per share
EPS
-$2.02
Free cash flow per share
-$1.52
Book value per share
$5.79
Revenue per share
$0
TBVPS
$6.13
Balance sheet
Total assets
$473.77M
Total liabilities
$43.83M
Debt
$17.42M
Equity
$429.94M
Working capital
$432.39M
Liquidity
Debt to equity
0.04
Current ratio
16.71
Quick ratio
16.44
Net debt/EBITDA
0.08
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30.9%
Return on equity
-33.5%
Return on invested capital
-34.2%
Return on capital employed
-31.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KURA stock price

How has the Kura Oncology stock price performed over time
Intraday
1.9%
1 week
2.98%
1 month
18.65%
1 year
-38.68%
YTD
-22.08%
QTD
6.03%

Financial performance

How have Kura Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$154.2M
Net income
-$142.96M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 12% YoY and by 4% QoQ
Kura Oncology's net income has decreased by 6% YoY and by 2.2% from the previous quarter

Growth

What is Kura Oncology's growth rate over time

Valuation

What is Kura Oncology stock price valuation
P/E
N/A
P/B
1.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The stock's P/B is 38% below its 5-year quarterly average of 2.7 and 7% below its last 4 quarters average of 1.8
The equity has contracted by 6% from the previous quarter but it has grown by 2.5% YoY

Efficiency

How efficient is Kura Oncology business performance
The return on equity has declined by 14% year-on-year
The ROA has contracted by 11% YoY
The return on invested capital has increased by 3.9% since the previous quarter but it has declined by 3.3% year-on-year

Dividends

What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KURA.

Financial health

How did Kura Oncology financials performed over time
KURA's total liabilities has soared by 55% year-on-year and by 25% since the previous quarter
The current ratio fell by 18% QoQ and by 5% YoY
The debt is 96% smaller than the equity
The debt is up by 34% since the previous quarter
The debt to equity has grown by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.